{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T07:03:34Z","timestamp":1648710214568},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[1998,8,1]],"date-time":"1998-08-01T00:00:00Z","timestamp":901929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[1998,8]]},"DOI":"10.1007\/s001340050675","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T07:30:30Z","timestamp":1030260630000},"page":"839-844","source":"Crossref","is-referenced-by-count":6,"title":["In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections"],"prefix":"10.1007","volume":"24","author":[{"given":"M.","family":"Araque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Velazco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"80240839134_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.9.1.1","volume":"9","author":"LE Nicolle","year":"1996","unstructured":"Nicolle LE, Strausbauch LJ, Garibaldi RA (1996) Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 9: 1\u201317","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 2","key":"80240839134_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003495-199600522-00020","volume":"52","author":"B Wiedemann","year":"1996","unstructured":"Wiedemann B (1996) Epidemiology, control and treatment of multiresistant gram-negative rods. Drugs 52 (Suppl 2):95\u2013102","journal-title":"Drugs"},{"key":"80240839134_CR3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0732-8893(95)00096-S","volume":"22","author":"PY Liu","year":"1995","unstructured":"Liu PY, Lau Y, Hu B, Shyr J, Shi Z, Tsai W, Lin Y, Tseng C (1995) Comparison of susceptibility to extended-spectrum \u03b2-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units. Diagn Microbiol Infect Dis 22: 285\u2013291","journal-title":"Diagn Microbiol Infect Dis"},{"key":"80240839134_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0732-8893(94)90033-7","volume":"19","author":"RN Jones","year":"1994","unstructured":"Jones RN, Kehrberg EN, Erwin ME, Anderson SC, Fluoroquinolone Resistance Surveillance Group (1994) Prevalence of important pathogens and antimicrobial activity of parental drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived? Diagn Microbiol Infect Dis 19: 203\u2013215","journal-title":"Diagn Microbiol Infect Dis"},{"key":"80240839134_CR5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/AAC.37.3.377","volume":"37","author":"LL Silver","year":"1993","unstructured":"Silver LL, Bostian KA (1993) Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimic-rob Agents Chemother 37: 377\u2013383","journal-title":"Antimic-rob Agents Chemother"},{"key":"80240839134_CR6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/science.8153624","volume":"264","author":"J Davies","year":"1994","unstructured":"Davies J (1994) Inactivation of antibiotics and the dissemination of resistance genes. Science 264: 375\u2013382","journal-title":"Science"},{"key":"80240839134_CR7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0732-8893(96)00099-5","volume":"25","author":"RN Jones","year":"1996","unstructured":"Jones RN (1996) The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on antibiotic resistance. Diagn Microbiol Infect Dis 25: 153\u2013161","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 2","key":"80240839134_CR8","first-page":"88","volume":"52","author":"DP Lew","year":"1996","unstructured":"Lew DP, Garbino J, Gerber AU, Sudre P (1996) The Swiss Committee of Anti-Infective Agents. Use of antimicrobials in Swiss hospitals. Drugs 52 (Suppl 2):88\u201391","journal-title":"Drugs"},{"key":"80240839134_CR9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","volume":"16","author":"JS Garner","year":"1988","unstructured":"Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections 1988. Am J Infect Control 16: 128\u2013140","journal-title":"Am J Infect Control"},{"key":"80240839134_CR10","volume-title":"Manual of clinical microbiology","author":"PR Murray","year":"1995","unstructured":"Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (1995) Manual of clinical microbiology. 6th edn. American Society Microbiology, Washington, DC","edition":"6th edn."},{"key":"80240839134_CR11","volume-title":"Approved standards M7-A3","author":"National Committee for Clinical Laboratory Standards (NCCLS)","year":"1994","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS) (1994) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd edn. Approved standards M7-A3. NCCLS, Villanova, PA","edition":"3rd edn."},{"issue":"Suppl 2","key":"80240839134_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00003495-199500492-00033","volume":"49","author":"RN Jones","year":"1995","unstructured":"Jones RN, Kehrberg EN, Erwin ME (1995) Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centers. Drugs 49 (Suppl 2):179\u2013181","journal-title":"Drugs"},{"key":"80240839134_CR13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.8.4.557","volume":"8","author":"DM Livermore","year":"1995","unstructured":"Livermore DM (1995) \u03b2-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8: 557\u2013584","journal-title":"Clin Microbiol Rev"},{"key":"80240839134_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0732-8893(94)90048-5","volume":"19","author":"RN Jones","year":"1994","unstructured":"Jones RN, Marshall SA (1994) Antimicrobial activity of cefepime tested against Bush group I \u03b2-lactamase-producing strains resistant to ceftazidime. Diagn Microbiol Infect Dis 19: 33\u201338","journal-title":"Diagn Microbiol Infect Dis"},{"key":"80240839134_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0732-8893(94)00087-D","volume":"21","author":"B Prosser","year":"1995","unstructured":"Prosser B La T, Beskid G (1995) Multi-center in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates. Diagn Microbiol Infect Dis 21: 33\u201345","journal-title":"Diagn Microbiol Infect Dis"},{"key":"80240839134_CR16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.2165\/00003495-199549050-00010","volume":"49","author":"JA Balfour","year":"1995","unstructured":"Balfour JA, Todd PA, Peters DH (1995) Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections. Drugs 49: 794\u2013850","journal-title":"Drugs"},{"issue":"Suppl 3A","key":"80240839134_CR17","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1016\/S0002-9343(20)31138-4","volume":"94","author":"CH Nightingale","year":"1993","unstructured":"Nightingale CH (1993) Overview of the pharmacokinetics of fleroxacin. Am J Med 94 (Suppl 3A):38S-43S","journal-title":"Am J Med"},{"key":"80240839134_CR18","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.36.9.1847","volume":"36","author":"N Masuda","year":"1992","unstructured":"Masuda N, Ohya S (1992) Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 36:1847\u20131851","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"80240839134_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2165\/00003495-199300453-00006","volume":"45","author":"JF Acar","year":"1993","unstructured":"Acar JF, O\u2019Brien TF, Goldstein FW, Jones RN (1993) The epidemiology of bacterial resistance to quinolones. Drugs 45 (Suppl 3):24\u201328","journal-title":"Drugs"},{"key":"80240839134_CR20","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/BF01975175","volume":"8","author":"JS Wolfson","year":"1989","unstructured":"Wolfson JS (1989) Quinolone antimicrobial agents: adverse effects and bacterial resistance. Eur J Clin Microbiol Infect Dis 8:1080\u20131092","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl A","key":"80240839134_CR21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/24.suppl_A.149","volume":"24","author":"DM Livermore","year":"1989","unstructured":"Livermore DM, Yang YJ (1989) Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. J Antimicrob Chemother 24 (Suppl A):191\u2013198","journal-title":"J Antimicrob Chemother"},{"key":"80240839134_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0732-8893(94)90089-2","volume":"18","author":"K Waites","year":"1994","unstructured":"Waites K, Rand K, Jenkins S, Yangco B, Brookings E, Gaskins D, Lewis J, Halkias K (1994) Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use. Diagn Microbiol Infect Dis 18:181\u2013189","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 2","key":"80240839134_CR23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003495-199500492-00042","volume":"49","author":"EJ Giamarellos-Bourboulis","year":"1995","unstructured":"Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H (1995) Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains. Drugs 49 (Suppl 2):203\u2013204","journal-title":"Drugs"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s001340050675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s001340050675\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s001340050675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T11:14:21Z","timestamp":1620040461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s001340050675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["80240839134"],"URL":"https:\/\/doi.org\/10.1007\/s001340050675","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]}}}